{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:02:29Z","timestamp":1783576949366,"version":"3.55.0"},"reference-count":74,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in controlling this disease. Stimulated NK cells have shown promise as a cellular therapy, but their application has been constrained by limited expansion capacity and low cytotoxic activity against CLL cells. Here, we demonstrate that both healthy donor-derived and CLL patient-derived NK cells expand rapidly when stimulated with feeder cells expressing membrane-bound interleukin-21 (mbIL-21) and have potent cytotoxic activity against allogeneic or autologous CLL cells. Combination with anti-CD20 antibodies significantly enhances NK recognition and killing of CLL targets. As any CLL immune therapy would likely be given in combination, we assess commonly used treatments and demonstrate that ibrutinib has mixed suppressive and protective effects on expanded NK cells, whereas expanded NKs are highly resistant to venetoclax. We demonstrate efficacy in\u00a0vivo in 2 xenograft mouse models of human CLL that support building upon a regimen of venetoclax and obinutuzumab with mbIL-21\u2013expanded NK cells. Collectively, these data support development of mbIL-21\u2013expanded NKs combined with the CD20 antibody obinutuzumab and venetoclax in the treatment of CLL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005883","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:59:31Z","timestamp":1651276771000},"page":"5641-5654","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of allogeneic and autologous membrane-bound IL-21\u2013expanded NK cells for chronic lymphocytic leukemia therapy"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-0093","authenticated-orcid":false,"given":"Max","family":"Yano","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia","family":"Sharpe","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Rachel","family":"Lance","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Ravikrishnan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan","family":"Zapolnik","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[{"name":"2The Ohio State University Center for Biostatistics, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"name":"4Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bhat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"},{"name":"5Division of Hematology-Oncology, Department of Pediatrics, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-4504","authenticated-orcid":false,"given":"Natarajan","family":"Muthusamy","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"3The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"11","key":"2023053013335874300_bib1","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/ijms22115536","article-title":"Current state of CAR T-cell therapy in chronic lymphocytic leukemia","volume":"22","author":"Mancikova","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2023053013335874300_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"22","key":"2023053013335874300_bib3","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2023053013335874300_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023053013335874300_bib5","doi-asserted-by":"crossref","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","volume":"5","author":"McWilliams","year":"2016","journal-title":"OncoImmunology"},{"issue":"5","key":"2023053013335874300_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2023053013335874300_bib7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2023053013335874300_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2011.313","article-title":"Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)","volume":"26","author":"Buechele","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2023053013335874300_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/eji.201141920","article-title":"4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia","volume":"42","author":"Buechele","year":"2012","journal-title":"Eur J Immunol"},{"issue":"6","key":"2023053013335874300_bib10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2010.74","article-title":"The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia","volume":"24","author":"N\u00fcckel","year":"2010","journal-title":"Leukemia"},{"issue":"18","key":"2023053013335874300_bib11","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023053013335874300_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10875-011-9624-5","article-title":"Primary B-CLL resistance to NK cell cytotoxicity can be overcome in\u00a0vitro and in\u00a0vivo by priming NK cells and monoclonal antibody therapy","volume":"32","author":"Veuillen","year":"2012","journal-title":"J\u00a0Clin Immunol"},{"issue":"2","key":"2023053013335874300_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","article-title":"Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells","volume":"63","author":"Kay","year":"1984","journal-title":"Blood"},{"issue":"3","key":"2023053013335874300_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ijc.2910270310","article-title":"Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia","volume":"27","author":"Ziegler","year":"1981","journal-title":"Int J Cancer"},{"issue":"42","key":"2023053013335874300_bib15","doi-asserted-by":"crossref","first-page":"68513","DOI":"10.18632\/oncotarget.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2023053013335874300_bib16","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"2023053013335874300_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000203709","article-title":"Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-\u03b1","volume":"96","author":"Katrinakis","year":"1996","journal-title":"Acta Haematol"},{"issue":"1","key":"2023053013335874300_bib18","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex\u00a0vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"2023053013335874300_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exphem.2010.02.006","article-title":"Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression","volume":"38","author":"Decot","year":"2010","journal-title":"Exp Hematol"},{"issue":"4","key":"2023053013335874300_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-017-2112-x","article-title":"Ex\u00a0vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells","volume":"67","author":"Nham","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2023053013335874300_bib21","doi-asserted-by":"crossref","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2023053013335874300_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"2023053013335874300_bib23","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex\u00a0vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023053013335874300_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13058-017-0867-9","article-title":"Ex\u00a0vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours","volume":"19","author":"Shenouda","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"10","key":"2023053013335874300_bib25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2326-6066.CIR-18-0144","article-title":"Expanded CD56superbrightCD16+ NK cells from ovarian cancer patients are cytotoxic against autologous tumor in a patient-derived xenograft murine model","volume":"6","author":"Poznanski","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2023053013335874300_bib26","doi-asserted-by":"crossref","first-page":"e27783","DOI":"10.1002\/pbc.27783","article-title":"Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells","volume":"66","author":"Ray","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2023053013335874300_bib27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2014.246","article-title":"Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells","volume":"29","author":"Fei","year":"2015","journal-title":"Leukemia"},{"issue":"16","key":"2023053013335874300_bib28","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex\u00a0vivo-expanded donor-derived NK cells after haploidentical transplantation [erratum]","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023053013335874300_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"issue":"26","key":"2023053013335874300_bib30","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10232","key":"2023053013335874300_bib31","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"2023053013335874300_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023053013335874300_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20160869","article-title":"Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival","volume":"214","author":"Viant","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"2023053013335874300_bib34","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2023053013335874300_bib35","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","article-title":"The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in\u00a0vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies","volume":"102","author":"Golay","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"2023053013335874300_bib36","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2023053013335874300_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2023053013335874300_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2023053013335874300_bib39","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.1992.tb04561.x","article-title":"B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-\u03b2","volume":"80","author":"Kremer","year":"1992","journal-title":"Br J Haematol"},{"issue":"10","key":"2023053013335874300_bib40","doi-asserted-by":"crossref","first-page":"e76607","DOI":"10.1371\/journal.pone.0076607","article-title":"Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in\u00a0vitro and in\u00a0vivo studies relevant to disease","volume":"8","author":"Hertlein","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2023053013335874300_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk Res"},{"key":"2023053013335874300_bib42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fimmu.2016.00454","article-title":"Activated allogeneic NK cells preferentially kill poor prognosis B-cell chronic lymphocytic leukemia cells","volume":"7","author":"S\u00e1nchez-Mart\u00ednez","year":"2016","journal-title":"Front Immunol"},{"issue":"6","key":"2023053013335874300_bib43","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"2023053013335874300_bib44","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1038\/cddis.2013.305","article-title":"CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex","volume":"4","author":"Maas","year":"2013","journal-title":"Cell Death Dis"},{"issue":"8","key":"2023053013335874300_bib45","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2003-10-3684","article-title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells","volume":"105","author":"Dicker","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2023053013335874300_bib46","first-page":"319","article-title":"Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells","volume":"36","author":"Sheard","year":"2013","journal-title":"J\u00a0Immunother"},{"issue":"9","key":"2023053013335874300_bib47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"2023053013335874300_bib48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3K\u03b4 inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol"},{"issue":"15","key":"2023053013335874300_bib49","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-16-1925","article-title":"Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex\u00a0vivo PI3K-\u03b4 inhibition","volume":"77","author":"Abu Eid","year":"2017","journal-title":"Cancer Res"},{"issue":"9","key":"2023053013335874300_bib50","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/eji.201948455","article-title":"Ex\u00a0vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells","volume":"50","author":"Dwyer","year":"2020","journal-title":"Eur J Immunol"},{"issue":"14","key":"2023053013335874300_bib51","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2023053013335874300_bib52","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2023053013335874300_bib53","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.celrep.2019.10.058","article-title":"Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity","volume":"29","author":"Pfefferle","year":"2019","journal-title":"Cell Rep"},{"issue":"6","key":"2023053013335874300_bib54","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.178.6.3575","article-title":"Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk","volume":"178","author":"Khurana","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"2023053013335874300_bib55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.179.2.551","article-title":"Phosphatidylinositol-3 kinase activation induced upon Fc gamma RIIIA-ligand interaction","volume":"179","author":"Kanakaraj","year":"1994","journal-title":"J\u00a0Exp Med"},{"issue":"28","key":"2023053013335874300_bib56","doi-asserted-by":"crossref","first-page":"23769","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2023053013335874300_bib57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/19420862.2015.989020","article-title":"Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies","volume":"7","author":"Duong","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"2023053013335874300_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023053013335874300_bib59","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023053013335874300_bib60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"2023053013335874300_bib61","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023053013335874300_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023053013335874300_bib63","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"2023053013335874300_bib64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023053013335874300_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.2830240207","article-title":"Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2","volume":"24","author":"Kay","year":"1987","journal-title":"Am J Hematol"},{"issue":"7","key":"2023053013335874300_bib66","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V76.7.1349.1349","article-title":"Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors","volume":"76","author":"Foa","year":"1990","journal-title":"Blood"},{"issue":"7","key":"2023053013335874300_bib67","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.V74.7.2464.2464","article-title":"Lymphokine-activated killer cell functions in patients with leukemic B-lymphoproliferative diseases","volume":"74","author":"van der Harst","year":"1989","journal-title":"Blood"},{"issue":"5-6","key":"2023053013335874300_bib68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428199209049804","article-title":"Resistance of chronic lymphocytic leukaemia cells to interferon-\u03b1 generated lymphokine activated killer cells","volume":"7","author":"Jewell","year":"1992","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2023053013335874300_bib69","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.leukres.2011.02.006","article-title":"Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia","volume":"35","author":"Eskelund","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"2023053013335874300_bib70","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.leu.2403083","article-title":"Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy","volume":"17","author":"Guven","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2023053013335874300_bib71","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"2023053013335874300_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03521.x","article-title":"Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia","volume":"135","author":"Costello","year":"2012","journal-title":"Immunology"},{"key":"2023053013335874300_bib73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fimmu.2015.00355","article-title":"IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells","volume":"6","author":"Ali","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"2023053013335874300_bib74","doi-asserted-by":"crossref","first-page":"15776","DOI":"10.1038\/ncomms15776","article-title":"IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours","volume":"8","author":"Seo","year":"2017","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/20\/5641\/2054070\/blooda_adv-2021-005883-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/20\/5641\/2054070\/blooda_adv-2021-005883-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:56:51Z","timestamp":1700517411000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/20\/5641\/485122\/Evaluation-of-allogeneic-and-autologous-membrane"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":74,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,10,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005883","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}